11SI Pediatric Constipation


To evaluate the long term safety and efficacy of Lubiprostone 12 or 24 mcg twice daily.


Contact Principal Investigator for Information


Processes: Patients completing the Sucampo 1131 trial that have shown good compliance will be offered the opportunity to participate in this trial.  The electronic diary will continue to be used to record constipation medications and bowel habits.  Lab be required at most visits.

Interested in more information? Contact Us:

Sunny Hussain, M.D., Principal Investigator
(318) 212-8130

IRB: Quorum
IRB Number:
Trial Type: Drug
Sponsor: Sucampo